This review highlights the potential of direct renin inhibitors like aliskiren as a novel therapeutic approach for managing hypertension and associated cardiovascular and renal diseases.
Answers are grounded in this paper and cite their sources.
Supports further study of direct renin inhibitors in hypertension; leaves open their clinical role pending randomized trials.
BACKGROUND: Direct renin inhibitors such as aliskiren offer a novel way of treating hypertension and its co-morbidities, conditions with a considerable prevalence, morbidity, and mortality worldwide. OBJECTIVE: The burden of hypertension worldwide and the role of the renin-angiotensin-aldosterone system in this disease will be reviewed. Current treatments for hypertension and its co-morbidities that work by manipulating this system will be discussed. The development of, and clinical trials involving, direct renin inhibitors will be reviewed, with a focus on aliskiren. METHODS: PubMed was utilized to search the most recent literature on the topics of the renin-angiotensin-aldosterone system, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosterone and aliskiren. RESULTS/CONCLUSIONS: The direct renin inhibitors, including aliskiren, are new agents with great promise for the treatment of hypertension and its co-morbid conditions, including renal and cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Siragy et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: